http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100361805-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-17013 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 |
| filingDate | 1999-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100361805-B1 |
| titleOfInvention | Preparation method of liquid-phase Lumbrokinase and anti-thrombotic agent thereof |
| abstract | The present invention relates to a liquid formulation method of lumpbrokinase capable of oral administration and to improved thrombolytic ability, and to liquid thrombosis according to the method. The liquid formulation method of lumpbrokinase according to the present invention comprises the steps of: mixing the purified lumpbrokinase in an alginate aqueous solution in a ratio of 5: 1; Preparing a mixture of 0.05% chitosan and 1.8% calcium chloride (chitosan-CaCl 2 ) to react with the alginate mixed aqueous solution; Mixing the alginate mixed aqueous solution with the stirred chitosan-calcium chloride mixed solution to form alginate / chitosan beads; Drying the alginate / chitosan beads, followed by washing with chitosan-calcium chloride and the same amount of distilled water to remove chitosan and calcium chloride adsorbed to the beads; Secondary beading the alginate / chitosan beads prepared in the primary into a chitosan / calcium chloride mixture; The secondary beaded alginate / chitosan beads are washed with distilled water, followed by drying to prepare alginate / chitosan gel beads. According to the configuration of the present invention as described above, it is possible to prevent the bleeding side effects due to the use of the injection, there is an advantage that can be prevented from inhibiting the enzyme activity during oral administration. |
| priorityDate | 1999-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.